canertinib has been researched along with Breast Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grunt, TW; Gschwantler-Kaulich, D; Kölbl, H; Muhr, D; Singer, CF; Wagner, R | 1 |
| Arun, BK; Franco, SX; Johnston, SR; Letrent, SP; Martin, M; Rixe, O; Rugo, HS; Yardley, DA | 1 |
| Benjaminsen, RV; Christiansen, IJ; Emdal, KB; Frogne, T; Kirkegaard, T; Lykkesfeldt, AE; Norrie, IC; Sonne-Hansen, K | 1 |
| Amir, E; Ocaña, A | 1 |
| Berger, W; Brünner-Kubath, C; Grunt, TW; Grusch, M; Marian, B; Saferding, V; Shabbir, W; Singer, CF; Valent, P; Wagner, R; Zielinski, CC | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Allen, LF; Eiseman, IA; Elliott, WL; Fry, DW; Lenehan, PF | 1 |
| Allen, LF; Eiseman, IA; Fry, DW; Lenehan, PF | 1 |
| Brose, MS; Flaherty, KT | 1 |
4 review(s) available for canertinib and Breast Neoplasms
| Article | Year |
|---|---|
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation | 2009 |
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Mice; Morpholines; Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2002 |
CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Ligands; Morpholines; Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2003 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
1 trial(s) available for canertinib and Breast Neoplasms
| Article | Year |
|---|---|
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Morpholines; Neoplasm Metastasis; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Receptors, Estrogen; Treatment Outcome | 2009 |
4 other study(ies) available for canertinib and Breast Neoplasms
| Article | Year |
|---|---|
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lapatinib; MAP Kinase Signaling System; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; STAT5 Transcription Factor | 2016 |
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Morpholines; Oncogene Proteins v-erbB; Signal Transduction | 2010 |
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Humans; Imidazoles; Molecular Targeted Therapy; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection | 2011 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |